These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2632261)

  • 1. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.
    Gabizon A; Peretz T; Sulkes A; Amselem S; Ben-Yosef R; Ben-Baruch N; Catane R; Biran S; Barenholz Y
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1795-803. PubMed ID: 2632261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
    Conley BA; Egorin MJ; Whitacre MY; Carter DC; Zuhowski EG; Van Echo DA
    Cancer Chemother Pharmacol; 1993; 33(2):107-12. PubMed ID: 8261569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
    Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N
    Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.
    Kattan J; Droz JP; Couvreur P; Marino JP; Boutan-Laroze A; Rougier P; Brault P; Vranckx H; Grognet JM; Morge X
    Invest New Drugs; 1992 Aug; 10(3):191-9. PubMed ID: 1428729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
    Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
    Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
    Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
    J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
    Matsumura Y; Gotoh M; Muro K; Yamada Y; Shirao K; Shimada Y; Okuwa M; Matsumoto S; Miyata Y; Ohkura H; Chin K; Baba S; Yamao T; Kannami A; Takamatsu Y; Ito K; Takahashi K
    Ann Oncol; 2004 Mar; 15(3):517-25. PubMed ID: 14998859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and upscaling of doxorubicin-containing liposomes for clinical use.
    Amselem S; Gabizon A; Barenholz Y
    J Pharm Sci; 1990 Dec; 79(12):1045-52. PubMed ID: 2079648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior.
    Goren D; Gabizon A; Barenholz Y
    Biochim Biophys Acta; 1990 Nov; 1029(2):285-94. PubMed ID: 2245212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
    Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
    J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
    Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
    Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
    Rahman A; Treat J; Roh JK; Potkul LA; Alvord WG; Forst D; Woolley PV
    J Clin Oncol; 1990 Jun; 8(6):1093-100. PubMed ID: 2348224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome.
    Junping W; Maitani Y; Takayama K; Nagai T
    Int J Pharm; 2000 Aug; 203(1-2):61-9. PubMed ID: 10967428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.